Xvivo Perfusion AB (publ) (XVIPY) Stock Price & Analysis
Xvivo Perfusion AB (publ) (XVIPY) — price $5.50 (+1924.69%), as of the Oct 23, 2026 trading session; market cap $693M.
Educational signal · not a buy or sell recommendation · How to read this
Xvivo Perfusion AB (publ) · XVIPY
Xvivo Perfusion AB (publ) is a medical technology company specializing in solutions for organ, tissue, and cell preservation and perfusion during transplantation. The company offers integrated systems and solutions like the XVIVO System (XPS) and STEEN Solution, serving a global market across North America, Europe, Asia Pacific, and other regions.
Price as of Oct 23, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $5.50 | |
| Change on the day | +1924.69% | |
| 52-week range | $4.25 – $8.18 | |
| Market capitalisation | $693M | |
| Price / earnings (trailing) | 50.46 | |
| Shares traded on the day | 1.0K |
Price & events
Other perspectives
Council score for Xvivo Perfusion AB (publ) (XVIPY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 26, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 26, 2026, except a card that shows its own read date.
Watch the XVIPY film — every key number, told as a short cinematic story
~2 min · open the film
What is Xvivo Perfusion AB (publ) (XVIPY), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Xvivo Perfusion AB (publ) (XVIPY) is the company analyzed here. It employs 210 people and is led by Christoffer Rosenblad. In Q3 FY2026 it reported revenue of $25M and net income of $4M. The market values it at $693M.
What do the latest results show for Xvivo Perfusion AB (publ) (XVIPY)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $25M. Against analyst estimates the company has EPS beat 4 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $25M | $4M | $0.04 (diluted) |
| Q2 FY2026 | $25M | $2M | $0.01 (diluted) |
| Q1 FY2026 | $25M | $4M | $0.03 (diluted) |
| Q4 FY2025 | $22M | $3M | $0.03 (diluted) |
What are the financial strengths and risks for Xvivo Perfusion AB (publ) (XVIPY)?
Short answer
The distress and quality screens read Altman Z 13.62 · Piotroski F 5. Trailing ratios: ROE 5.9% · ROA 5.0% · current ratio 3.91 · earnings yield 1.8% · free-cash-flow yield 2.7%.
Common Questions About XVIPY
These answers are editorial: 1 of these 8 answers is drawn from the XVIPY research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is XVIPY a good stock to buy?
Stock Expert AI does not rate XVIPY buy, sell or hold. Xvivo Perfusion AB (publ) has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the XVIPY stock price today?
The last price recorded on this page for Xvivo Perfusion AB (publ) (XVIPY) is $5.50, as of the Oct 23, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for XVIPY?
XVIPY faces several notable risks that investors may want to evaluate. A primary risk is the intense competition within the medical device industry, where larger, more diversified companies with greater financial and R&D resources could pose a significant challenge.
What are the key factors to evaluate for XVIPY?
Evaluate XVIPY on fundamentals, analyst consensus, and risk factors. P/E: 50.46x. Xvivo's solutions, particularly those that enable the use of marginal organs, are critical enablers in this trend. Not financial advice.
How frequently does XVIPY data refresh on this page?
XVIPY's price is the last quote we recorded, from the Oct 23, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven XVIPY's recent stock price performance?
Xvivo Perfusion AB (publ) (XVIPY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized and comprehensive product portfolio for organ preservation and perfusion. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider XVIPY overvalued or undervalued right now?
Xvivo Perfusion AB (publ) (XVIPY) trades at 50.46x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research XVIPY before investing?
Before investing in Xvivo Perfusion AB (publ) (XVIPY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (15 figures)
The 15 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 9 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $5.50 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T08:44:38.166Z. | |
px.change | Change on the day | +1924.69% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $693M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-09-30. FMP quote timestamp: 2026-09-30T20:00:00.000Z. Captured from FMP at 2026-10-26T08:44:36.488Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 50.46 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.0K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q3 FY2026 | $25M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q3 FY2026 | $4M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q3 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $4.25 – $8.18 | UNRECORDED | Stored company-profile observation — Captured 2026-10-23 | |
id.employees | Employees | 210 | UNRECORDED | Stored company-profile observation — Captured 2026-10-23 | |
id.ceo | Chief executive | Christoffer Rosenblad | UNRECORDED | Stored company-profile observation — Captured 2026-10-23 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-12 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 13.62 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-25 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 5.9% · ROA 5.0% · current ratio 3.91 · earnings yield 1.8% · free-cash-flow yield 2.7% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.